Related Experiment Video
Updated: Oct 28, 2025
10:41
Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
7.6K
Tremor in Primary Monogenic Dystonia.
Sanjay Pandey1, Sonali Bhattad2, Shreya Dinesh2
1Department of Neurology, Govind Ballabh Pant Postgraduate Institute of Medical Education and Research, Academic Block, Room No 501, New Delhi, 110002, India. sanjaysgpgi2002@yahoo.co.in.
Current Neurology and Neuroscience Reports
|July 15, 2021
Summary
Tremor is a common dystonia symptom, but prevalence varies. This review found tremor in nine primary monogenic dystonia genes, with DYT-HPCA and DYT-ANO3 showing high prevalence in isolated dystonia.
Area of Science:
- Neurology
- Genetics
- Movement Disorders
Background:
- Tremor is a key feature of dystonia, with reported prevalence varying widely (14-86.67%).
- This variability may stem from different dystonia types studied.
- Understanding tremor in primary monogenic dystonia is crucial for diagnosis and treatment.
Purpose of the Study:
- To review research on tremor prevalence in primary monogenic dystonia.
- To identify specific genes associated with tremor in dystonia.
Main Methods:
- Searched the MDS gene database for research articles on tremor in primary monogenic dystonia.
- Analyzed reported frequencies of tremor across different dystonia genes.
Main Results:
- Tremor was identified in nine primary monogenic dystonia genes (DYT-HPCA, DYT-ANO3, DYT-KCTD17, DYT-THAP1, DYT-PRKRA, DYT-GNAL, DYT-TOR1A, DYT-KMT2B, DYT-SGCE).
- DYT-HPCA and DYT-ANO3 showed the highest tremor prevalence in isolated dystonia.
- DYT-SLC6A3 exhibited the highest tremor prevalence in dystonia parkinsonism.
Conclusions:
- Specific genes are frequently associated with tremor in primary monogenic dystonia.
- Gene identification aids in understanding tremor's role in dystonia phenotypes.
- Further research can refine the understanding of tremor in genetic dystonia subtypes.
Related Concept Videos
01:26Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin
862
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
The binding of dantrolene to the RYR1...
862
01:28Disorders of the Skeletal Muscle
1.3K
The clinical conditions affecting the skeletal muscle tissue are broadly categorized as musculoskeletal and neuromuscular disorders.
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
Musculoskeletal disorders
Musculoskeletal disorders involve injuries and conditions affecting the skeletal muscles and associated connective tissues. These disorders can arise from acute biomechanical stresses or chronic overuse and can occur across different age groups. Common injuries include sprains, fractures, and muscular strains, often resulting from...
1.3K
01:15Parkinson's Disease: Overview
993
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
993
01:24Parkinson's Disease: Treatment
569
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
569
01:28Classification of Skeletal Muscle Relaxants
2.8K
Skeletal muscle relaxants are a group of drugs that can reduce muscle stiffness and induce temporary paralysis to relieve pain. These agents can act centrally to reduce muscle tone or spasms in painful conditions such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), or spinal injuries; they are called antispasmodics or spasmolytics.
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
Peripherally acting skeletal muscle relaxants interfere with the neurotransmission at the neuromuscular end plate to induce paralysis during...
2.8K
01:21Skeletal Muscle Relaxants: Adverse Effects
547
Skeletal muscle relaxants are widely used for muscle paralysis and relieving pain following any muscle injury or stiffness. However, depending on the drug type, they can have adverse effects that range from mild to severe. Usually, nondepolarizing neuromuscular blockers have minimal side effects. For example, drugs like d-tubocurarine, cisatracurium, and rocuronium cause hypotension, whereas drugs like baclofen, when stopped abruptly, can lead to the recurrence of spastic conditions.
Unlike...
Unlike...
547